The Structure team traded the office for the starting line at this year’s San Francisco J.P. Morgan Corporate Challenge! It was a great opportunity to come together outside of our day-to-day, enjoy some friendly competition, and share a few miles as a team. Thanks to everyone who joined us for an evening of movement, connection, and team spirit! #JPMCC

We're pleased to report positive clinical results from our two lead product candidates: ACCG-2671, an oral small-molecule dual amylin and calcitonin receptor agonist (DACRA) and aleniglipron, an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. Together, these programs advance our goal of creating a best-in-industry oral chronic weight management portfolio for patients at different stages in their treatment journey. ir.structuretx.com/news-rele…

Today, we reported financial results for the second quarter ended June 30, 2026 and provided a business update including the initiation of the Phase 3 ACCOMPLISH program evaluating aleniglipron for the treatment of #obesity. Read more here: ir.structuretx.com/news-rele…

Thanks to everyone who stopped by our table at the @ObesityAction's Your Weight Matters National Convention! It was a privilege to connect with members of the #obesity community, share stories and focus on how these experiences shape the future of obesity care. We're grateful to the OAC for bringing together a community dedicated to education, advocacy and support. #YWM2026

We're proud to sponsor the @ObesityAction's Your Weight Matters National Convention, where individuals, families, healthcare professionals, and advocates come together to advance education, support, and conversations around #obesity care. If you're attending #YWM2026, stop by our table to learn more about our mission to make medicines more accessible.

Our CEO joined @CNBC's at #ADASciSessions to discuss why accessibility is at the heart of the evolving weight loss market and how our once-daily oral #GLP1 aleniglipron, with potential market launch expected by 2029, is designed to reach more patients globally. cnbc.com/video/2026/06/09/st…

Data from the Phase 2b ACCESS trial of aleniglipron, our once-daily oral #GLP1 pill, has been published in Nature Medicine and was presented today at the 86th #ADASciSessions. Key findings include: ➡️Up to 16.2% body weight loss at 56 weeks with continued weight loss and no apparent plateau, and ➡️a low 10.4% overall discontinuation rate. Phase 3 remains on track for Q3 2026. Read more: ir.structuretx.com/news-rele…

The patient voice matters at every table. It guides how we partner with patients and physicians and shape programs to make a real difference for people living with #obesity. Our executive director, medical affairs & advocacy engagement shares more below. ⬇️

On #ClinicalTrialsDay, we're thinking about the participants in our studies, the investigators, coordinators, and study teams beside them, and the families who make every visit possible. Our mission is to deliver oral #smallmolecule medicines that are more scalable, manufacturable, and broadly accessible because innovation only matters if it reaches the patients it's meant to serve.

Today, we reported financial results for the first quarter ended March 31, 2026, and provided a business update. Top highlights include: 📉Positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point; 🔎Aleniglipron, amylin and combination data to be presented at the 86th #ADASciSessions ▶️Data from ACCESS OLE expected in Q3 2026, and ongoing body composition and type 2 diabetes/obesity studies expected in Q4 2026; 📊Initial data from Phase 1 SAD study of oral small molecule amylin receptor agonist ACCG-2671 and initiation of MAD study expected in Q3 2026; Read the full announcement: ir.structuretx.com/news-rele…

We’re heading to the 86th #ADASciSessions to showcase aleniglipron in multiple presentations share new data across ACCESS, including its class-leading efficacy along with tolerability and safety data for aleniglipron, plus new amylin #smallmolecule and preclinical combination data. View the details here: ir.structuretx.com/news-rele…

We continue to remember Danielle Keatley, a deeply respected and valued member of our biotech community. She had a genuine passion for our company's mission to expand access to medicines, and her presence left a lasting impact on those who worked alongside her. We'll carry her memory with us and remain committed to honoring her legacy. In her honor, a memorial fund has been established, and a celebration of life will be held on Sunday, April 26. You can find more about Danielle’s life, along with details on the memorial fund and upcoming celebration of life, here. legacy.com/legacy/danielle-k…

We’re pleased to welcome Matthew Lang, J.D. as Chief Operating Officer and General Counsel at Structure Therapeutics. With 15+ years of leadership across global biopharma, his experience will support our next phase of growth as we advance aleniglipron into Phase 3. Read more: ir.structuretx.com/news-rele…

Our CEO appeared on @SquawkStreet to discuss the latest Phase 2 data for aleniglipron, our once-daily #GLP1 oral pill, which demonstrated best-in-class efficacy and off-target safety, and low, single-digit discontinuation rates. The progress we’re seeing broadly reinforces that oral approaches to #obesity are becoming effective.

Our Phase 2 ACCESS II trial data marks an important milestone for the tens of millions of people living with #obesity and the physicians who care for them. As we prepare for Phase 3, the data reinforce aleniglipron's potential to become an important and more convenient option within one of the largest global therapeutic categories.

We're pleased to announce positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with #obesity and/or overweight with at least one weight related co-morbidity. This includes 44-week data from the Phase 2 ACCESS II study and interim data from the ongoing body composition study and the ACCESS open label extension study. Read more: ir.structuretx.com/news-rele…

Today, we reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. Top highlights include: 📊Topline 44-week data from ACCESS II study with higher doses expected in Q1 2026; ▶️Aleniglipron Phase 3 initiation expected in 2H 2026; 📈Initial data from Phase 1 study of oral small molecule amylin receptor agonist ACCG-2671 and Phase 1 initiation of second oral #amylin compound ACCG-3535 expected in 2H 2026. Read the full announcement: ir.structuretx.com/news-rele…